Literature DB >> 23804638

Coagulation factor binding orientation and dimerization may influence infectivity of adenovirus-coagulation factor complexes.

Eric E Irons1, Justin W Flatt, Konstantin Doronin, Tara L Fox, Mauro Acchione, Phoebe L Stewart, Dmitry M Shayakhmetov.   

Abstract

Adenoviruses (Ads) are promising vectors for therapeutic interventions in humans. When injected into the bloodstream, Ad vectors can bind several vitamin K-dependent blood coagulation factors, which contributes to virus sequestration in the liver by facilitating transduction of hepatocytes. Although both coagulation factors FVII and FX bind the hexon protein of human Ad serotype 5 (HAdv5) with a very high affinity, only FX appears to play a role in mediating Ad-hepatocyte transduction in vivo. To understand the discrepancy between efficacy of FVII binding to hexon and its apparently poor capacity for supporting virus cell entry, we analyzed the HAdv5-FVII complex by using high-resolution cryo-electron microscopy (cryo-EM) followed by molecular dynamic flexible fitting (MDFF) simulations. The results indicate that although hexon amino acids T423, E424, and T425, identified earlier as critical for FX binding, are also involved in mediating binding of FVII, the FVII GLA domain sits within the surface-exposed hexon trimer depression in a different orientation from that found for FX. Furthermore, we found that when bound to hexon, two proximal FVII molecules interact via their serine protease (SP) domains and bury potential heparan sulfate proteoglycan (HSPG) receptor binding residues within the dimer interface. In contrast, earlier cryo-EM studies of the Ad-FX interaction showed no evidence of dimer formation. Dimerization of FVII bound to Ad may be a contributing mechanistic factor for the differential infectivity of Ad-FX and Ad-FVII complexes, despite high-affinity binding of both these coagulation factors to the virus.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23804638      PMCID: PMC3754089          DOI: 10.1128/JVI.01070-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

2.  Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

Authors:  Raul Alba; Angela C Bradshaw; Alan L Parker; David Bhella; Simon N Waddington; Stuart A Nicklin; Nico van Rooijen; Jerome Custers; Jaap Goudsmit; Dan H Barouch; John H McVey; Andrew H Baker
Journal:  Blood       Date:  2009-05-08       Impact factor: 22.113

3.  Flexible fitting of atomic structures into electron microscopy maps using molecular dynamics.

Authors:  Leonardo G Trabuco; Elizabeth Villa; Kakoli Mitra; Joachim Frank; Klaus Schulten
Journal:  Structure       Date:  2008-05       Impact factor: 5.006

4.  Visualization of alpha-helices in a 6-angstrom resolution cryoelectron microscopy structure of adenovirus allows refinement of capsid protein assignments.

Authors:  Susan D Saban; Mariena Silvestry; Glen R Nemerow; Phoebe L Stewart
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

5.  Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks.

Authors:  Hongrong Liu; Lei Jin; Sok Boon S Koh; Ivo Atanasov; Stan Schein; Lily Wu; Z Hong Zhou
Journal:  Science       Date:  2010-08-27       Impact factor: 47.728

6.  Crystal structure of human adenovirus at 3.5 A resolution.

Authors:  Vijay S Reddy; S Kundhavai Natchiar; Phoebe L Stewart; Glen R Nemerow
Journal:  Science       Date:  2010-08-27       Impact factor: 47.728

7.  Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.

Authors:  O Kalyuzhniy; N C Di Paolo; M Silvestry; S E Hofherr; M A Barry; P L Stewart; D M Shayakhmetov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

8.  Adenovirus serotype 5 hexon mediates liver gene transfer.

Authors:  Simon N Waddington; John H McVey; David Bhella; Alan L Parker; Kristeen Barker; Hideko Atoda; Rebecca Pink; Suzanne M K Buckley; Jenny A Greig; Laura Denby; Jerome Custers; Takashi Morita; Ivo M B Francischetti; Robson Q Monteiro; Dan H Barouch; Nico van Rooijen; Claudio Napoli; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

Review 9.  The influence of blood on in vivo adenovirus bio-distribution and transduction.

Authors:  Andrew H Baker; John H Mcvey; Simon N Waddington; Nelson C Di Paolo; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2007-05-15       Impact factor: 11.454

10.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.

Authors:  Alan L Parker; Simon N Waddington; Campbell G Nicol; Dmitry M Shayakhmetov; Suzanne M Buckley; Laura Denby; Geoffrey Kemball-Cook; Shaoheng Ni; Andre Lieber; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

View more
  14 in total

Review 1.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

2.  The Inflammatory and Fibrotic Patterns of Hepatic Stellate Cells Following Coagulation Factors (VII or X)-Shielded Adenovirus Infection.

Authors:  Alireza Shiri; Jamal Sarvari; Saeed Firoozi Ghahestani; Nasser Gholijani; Ali Mohammad Tamaddon; Mahroo Rastegari; Afagh Moattari; Seyed Younes Hosseini
Journal:  Curr Microbiol       Date:  2021-01-07       Impact factor: 2.188

3.  Human full-length coagulation factor X and a GLA domain-derived 40-mer polypeptide bind to different regions of the adenovirus serotype 5 hexon capsomer.

Authors:  Sudir Sumarheni; Saw See Hong; Véronique Josserand; Jean-Luc Coll; Pierre Boulanger; Guy Schoehn; Pascal Fender
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

4.  Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.

Authors:  Jiangtao Ma; Margaret R Duffy; Lin Deng; Rachel S Dakin; Taco Uil; Jerome Custers; Sharon M Kelly; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  PLoS Pathog       Date:  2015-02-06       Impact factor: 6.823

5.  Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum.

Authors:  Andrew W Harmon; Rituparna Moitra; Zhili Xu; Andrew P Byrnes
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

6.  Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum.

Authors:  Estrella Lopez-Gordo; Andor Doszpoly; Margaret R Duffy; Lynda Coughlan; Angela C Bradshaw; Katie M White; Laura Denby; Stuart A Nicklin; Andrew H Baker
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

Review 7.  Recent advances in genetic modification of adenovirus vectors for cancer treatment.

Authors:  Yuki Yamamoto; Masaki Nagasato; Teruhiko Yoshida; Kazunori Aoki
Journal:  Cancer Sci       Date:  2017-05-07       Impact factor: 6.716

8.  Adenovirus flow in host cell networks.

Authors:  Justin W Flatt; Sarah J Butcher
Journal:  Open Biol       Date:  2019-02-28       Impact factor: 6.411

Review 9.  Gene Therapy Leaves a Vicious Cycle.

Authors:  Reena Goswami; Gayatri Subramanian; Liliya Silayeva; Isabelle Newkirk; Deborah Doctor; Karan Chawla; Saurabh Chattopadhyay; Dhyan Chandra; Nageswararao Chilukuri; Venkaiah Betapudi
Journal:  Front Oncol       Date:  2019-04-24       Impact factor: 6.244

Review 10.  Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Authors:  Hanni Uusi-Kerttula; Sarah Hulin-Curtis; James Davies; Alan L Parker
Journal:  Viruses       Date:  2015-11-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.